281
Participants
Start Date
May 13, 2021
Primary Completion Date
July 8, 2022
Study Completion Date
October 27, 2022
LY3437943
Administered SC
Dulaglutide
Administered SC
Placebo
Administered SC
Manati Center for Clinical Research, Manatí
Latin Clinical Trial Center, San Juan
Heritage Valley Medical Group, Inc., Beaver
Preferred Primary Care Physicians, Pittsburgh
Preferred Primary Care Physicians, Uniontown
Frontier Clinical Research, LLC, Smithfield
Centennial Medical Group, Elkridge
The Research Center of The Upstate, Greenville
South Florida Clinical Research Institute, Margate
Encore Medical Research - Weston, Weston
ForCare Clinical Research, Tampa
Syed Research Consultants Llc, Sheffield
MediSync Clinical Research, Petal
Iowa Diabetes and Endocrinology Research Center, West Des Moines
Lillestol Research, Fargo
Logan Health Research, Kalispell
Clinvest Research LLC, Springfield
Cotton O'Neil Clinic, Topeka
Intend Research, LLC, Norman
Southern Endocrinology Associates, Mesquite
Dallas Diabetes Research Center, Dallas
Diabetes and Thyroid Center of Fort Worth, Fort Worth
North Hills Family Medicine/North Hills Medical Research, North Richland Hills
Endocrine Ips, Pllc, Houston
Laila A Hassan, MD, PA, Houston
Elite Clinical Trials, Blackfoot
Rocky Mountain Clinical Research, Idaho Falls
Elite Clinical Trials, Rexburg
Humphreys Diabetes Center, Boise
National Research Institute - Huntington Park, Huntington Park
San Fernando Valley Health Institute, Canoga Park
National Research Institute - Panorama City, Panorama City
Catalina Research Institute, LLC, Montclair
Artemis Institute for Clinical Research, San Diego
Anderson Clinical Research, Redlands
Artemis Institute for Clinical Research, Riverside
National Research Institute (NRI) - Santa Ana, Santa Ana
Valley Endocrine, Fresno, Fresno
Diablo Clinical Research, Inc., Walnut Creek
Rainier Clinical Research Center, Renton
Universal Research Group, Tacoma
The Vancouver Clinic, Vancouver
Advanced Clinical Research, LLC, Bayamón
Eli Lilly and Company
INDUSTRY